Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 6/20 | 0.54 |
| ▸ | ABL1 | P00519 | 8/20 | 0.51 |
| ▸ | BCR | P11274 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2924553 | 0.87 | ABL1 (0.64) | MAPK10ABL1BCRRIPK2RET | |
| SCHEMBL3564824 | 0.83 | ABL1 (0.49) | ABL1BCR | |
| SCHEMBL14705593 | 0.81 | ABL1 (0.55) | ABL1BCRLCKKDR | |
| SCHEMBL3554974 | 0.79 | ALDH1A1 (0.48) | MAPK10ABL1 | |
| SCHEMBL13316450 | 0.79 | KARS1 (0.50) | MAPK10ABL1BCRLCKKDR | |
| SCHEMBL2575958 | 0.77 | ABL1 (0.78) | ABL1BCRLCK | |
| SCHEMBL3565337 | 0.76 | ABL1 (0.66) | ABL1BCRKARS1 | |
| SCHEMBL26778048 | 0.75 | ABL1 (0.45) | ABL1BCRLCK | |
| SCHEMBL22793758 | 0.71 | ABL1 (0.70) | ABL1BCRRIPK2RETKDR | |
| SCHEMBL1518724 | 0.70 | MAPK10 (1.00) | MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-1533304-B1 | AMIDE DERIVATIVE | NIPPON SHINYAKU CO LTD (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7494997-B2 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-20060014742-A1 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1533304-A1 | AMIDE DERIVATIVE | Nippon Shinyaku Co., Ltd. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014742-A1 | Amide derivative | ABL1, ABL2, BCR | MAPK10 441/4885ABL1 1/4885BCR 3/4885 |
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | MAPK10 453/4885ABL1 2/4885BCR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.